Evidence explainerWomen's GLP-1 & Weight
GLP-1s With PCOS or After Menopause: What the Evidence Shows
In women with PCOS, GLP-1 drugs produce modest weight loss in small trials, with little proof yet for cycles or fertility. After menopause, one small study found more weight loss on semaglutide in women using hormone therapy.
Key takeaways
- A 2026 meta-analysis of 11 randomized trials in women with PCOS found GLP-1 drugs added a modest BMI reduction of 1.38 kg/m2 (low certainty); evidence on cycles, excess hair, glucose and insulin was insufficient [1].
- The 2023 international PCOS guideline says anti-obesity medicines may be considered as in the general population, but recommends using them for reproductive outcomes only in research settings [2].
- The guideline asks clinicians to ensure effective contraception for women on GLP-1 drugs who could become pregnant, because pregnancy safety data are lacking [2].
- In a Mayo Clinic records study of 106 postmenopausal women on semaglutide, the 16 using menopause hormone therapy lost 16% of body weight at 12 months vs 12% for the rest; the authors call for larger studies [3].
- Tirzepatide can make birth-control pills less reliable [4], and Wegovy's label says to stop semaglutide at least 2 months before a planned pregnancy [5].
PCOS: what the trials show
A 2026 systematic review searched for randomized trials of GLP-1 drugs in women with PCOS and found 11. Added to other care, GLP-1 drugs reduced BMI by 1.38 kg/m2 more than controls, rated low certainty; there was no difference in LDL cholesterol or triglycerides, and the evidence was insufficient to judge glucose, insulin, excess hair or menstrual regularity [1].
No trial in the review measured quality of life, mental health or cost-effectiveness [1]. PCOS was renamed PMOS in 2026; our PCOS hub covers diagnosis and first-line treatment.
PCOS: what the guideline says
The 2023 international guideline says anti-obesity medicines and bariatric surgery may be considered in PCOS based on general-population guidelines, balancing benefits and side effects [2]. For fertility, it recommends using anti-obesity agents for reproductive outcomes only in research settings until their efficacy and safety are established [2].
It also tells clinicians to ensure effective contraception whenever pregnancy is possible for women taking GLP-1 receptor agonists, because pregnancy safety data are lacking [2]. Our GLP-1, the pill and pregnancy guide explains the label warnings.
After menopause: does hormone therapy change the response?
A retrospective Mayo Clinic study followed 106 postmenopausal women prescribed semaglutide for at least 3 months. The 16 women using menopause hormone therapy lost more weight at every checkpoint, 16% vs 12% of body weight at 12 months, and the difference held after adjusting for other factors [3].
With only 16 women on hormone therapy and no randomization, the study cannot show that hormone therapy causes the extra weight loss; the authors say larger studies are needed [3]. Our menopause hub covers who hormone therapy suits.
Muscle and bone after menopause
A 2025 joint advisory names older, perimenopausal and menopausal women among those most exposed to muscle loss when low appetite cuts protein intake, and recommends strength training at least 3 times a week to preserve muscle and bone [6]. Our GLP-1 muscle guide has the targets.
Partners we link to
- GalaPaid linkWomen-focused online weight care: compounded semaglutide or tirzepatide (not FDA-approved) at a published flat $179/mo on a yearly subscription, visits and shipping included (checked Oct 8, 2026). LegitScript certified.See Gala's GLP-1 plans
- FoundPaid linkWeight care with named board-certified clinicians: brand-name GLP-1 prescriptions (medication billed separately, insurance accepted) or compounded semaglutide and tirzepatide, which are not FDA-approved. LegitScript certified.See Found's weight plans
Quick answers
Will a GLP-1 regulate my periods if I have PCOS?
It is not yet known. A 2026 meta-analysis of 11 trials found the evidence on menstrual regularity insufficient to draw conclusions [1].
More in Women's GLP-1 & Weight
- Women's GLP-1 & Weight hub
- Semaglutide vs Tirzepatide: How Much Weight the Trials Showed, and What Happens When You Stop
- Compounded Semaglutide and Tirzepatide: What the FDA Actually Says, and the Red Flags to Check
- GLP-1s, the Pill and Pregnancy: The Label Warnings Women Need Before Starting
- GLP-1s and Muscle: How Much Lean Mass Women Lose, and the Protein and Strength Plan Experts Recommend
- Hair Shedding on Semaglutide or Tirzepatide: How Common It Is in Women, and Whether Iron Matters
References
- [1]GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis. Eur J Endocrinol, 2026.
- [2]Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab, 2023.
- [3]Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 2024.
- [4]ZEPBOUND (tirzepatide) injection: prescribing information. U.S. Food and Drug Administration (Drugs@FDA), 2026.
- [5]WEGOVY (semaglutide) injection and tablets: prescribing information. U.S. Food and Drug Administration (Drugs@FDA), 2026.
- [6]Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obes Pillars, 2025.